We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

13 hedge funds and large institutions have $46.6M invested in Palvella Therapeutics in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
13
Holders Change
+13
Holders Change %
–
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
O
OrbiMed
New York
+$20M
2
TCM
Tekla Capital Management
Massachusetts
+$10.6M
3
LOAMU
Lombard Odier Asset Management (USA)
New York
+$7.12M
4
SFM
Sphera Funds Management
Israel
+$3.3M
5
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$2.49M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$20M +$20M +90,745 New
TCM
2
Tekla Capital Management
Massachusetts
$10.6M +$10.6M +48,102 New
LOAMU
3
Lombard Odier Asset Management (USA)
New York
$7.13M +$7.12M +32,386 New
SFM
4
Sphera Funds Management
Israel
$3.3M +$3.3M +15,000 New
EMFAT
5
Emerald Mutual Fund Advisers Trust
Pennsylvania
$2.49M +$2.49M +11,320 New
GOCM
6
Green Owl Capital Management
New York
$1.24M +$1.24M +5,625 New
PRCM
7
Pine River Capital Management
Minnesota
$963K +$963K +4,375 New
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$356K +$356K +1,617 New
DCM
9
DAFNA Capital Management
California
$344K +$344K +1,563 New
EA
10
Emerald Advisers
Pennsylvania
$144K +$144K +653 New
TDC
11
Thompson Davis & Co
Virginia
$62K +$61.8K +281 New
UBS Group
12
UBS Group
Switzerland
$17K +$16.7K +76 New
TRCT
13
Tower Research Capital (TRC)
New York
$1K +$1.32K +6 New

PVLA Hedge Fund Activity: Q2 2015 in Review

13 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2015, worth a combined $46.6M.

Buyers outnumbered sellers: 13 funds opened new PVLA positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $20M.

  • 13 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2015, up from 0 in Q1 2015.
  • Funds reported $46.6M of Palvella Therapeutics stock for Q2 2015.
  • 13 funds opened new Palvella Therapeutics positions in Q2 2015 and 0 closed out, a net change of +13 holders.
  • The largest Palvella Therapeutics buyer in Q2 2015 was OrbiMed, an estimated $20M added.

Based on aggregated 13F filings for Q2 2015.